X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19340) 19340
Book Review (3864) 3864
Newsletter (1214) 1214
Publication (1178) 1178
Magazine Article (162) 162
Conference Proceeding (153) 153
Book Chapter (113) 113
Newspaper Article (87) 87
Dissertation (36) 36
Trade Publication Article (31) 31
Web Resource (12) 12
Book / eBook (7) 7
Transcript (6) 6
Paper (3) 3
Reference (2) 2
Data Set (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13719) 13719
humans (12424) 12424
proton pump inhibitors (12022) 12022
male (6370) 6370
female (5878) 5878
gastroenterology & hepatology (4890) 4890
middle aged (4526) 4526
proton pump inhibitors - therapeutic use (3882) 3882
adult (3798) 3798
aged (3503) 3503
omeprazole (3329) 3329
pharmacology & pharmacy (3070) 3070
proton pump inhibitor (2761) 2761
treatment outcome (2576) 2576
gastroesophageal reflux - drug therapy (2337) 2337
risk factors (2256) 2256
gastroesophageal reflux (2190) 2190
helicobacter pylori (2166) 2166
helicobacter infections - drug therapy (1933) 1933
animals (1926) 1926
lansoprazole (1871) 1871
proton pump inhibitors - adverse effects (1725) 1725
anti-ulcer agents - therapeutic use (1679) 1679
abridged index medicus (1633) 1633
drug therapy, combination (1583) 1583
therapy (1553) 1553
medicine, general & internal (1467) 1467
proton pump inhibitors - administration & dosage (1427) 1427
care and treatment (1422) 1422
aged, 80 and over (1292) 1292
omeprazole - therapeutic use (1255) 1255
2-pyridinylmethylsulfinylbenzimidazoles (1231) 1231
medicine & public health (1223) 1223
hydrogen-ion concentration (1218) 1218
risk (1217) 1217
research (1202) 1202
gastroesophageal reflux disease (1152) 1152
health aspects (1145) 1145
gastroesophageal-reflux disease (1144) 1144
omeprazole - analogs & derivatives (1120) 1120
drug therapy (1099) 1099
retrospective studies (1091) 1091
proton-pump inhibitors (1081) 1081
anti-bacterial agents - therapeutic use (1074) 1074
adolescent (1053) 1053
prospective studies (1035) 1035
disease (1014) 1014
management (1005) 1005
histamine h2 antagonists - therapeutic use (997) 997
time factors (991) 991
gastroesophageal reflux - diagnosis (980) 980
rabeprazole (976) 976
infection (942) 942
double-blind (940) 940
pantoprazole (918) 918
surgery (915) 915
drug interactions (911) 911
gastroesophageal reflux - complications (900) 900
diagnosis (897) 897
young adult (876) 876
prevalence (866) 866
gastroenterology (856) 856
medical research (854) 854
endoscopy (790) 790
helicobacter pylori - drug effects (779) 779
proton pump (777) 777
esomeprazole (773) 773
analysis (768) 768
dosage and administration (764) 764
medicine, experimental (760) 760
internal medicine (754) 754
pharmacokinetics (733) 733
metaanalysis (729) 729
anti-ulcer agents - administration & dosage (726) 726
proton pump inhibitors - pharmacology (718) 718
complications and side effects (715) 715
omeprazole - administration & dosage (714) 714
rats (693) 693
esophagitis (683) 683
symptoms (679) 679
clopidogrel (669) 669
dose-response relationship, drug (667) 667
usage (663) 663
omeprazole - pharmacology (657) 657
biochemistry & molecular biology (656) 656
drug administration schedule (648) 648
oncology (642) 642
helicobacter-pylori infection (638) 638
follow-up studies (635) 635
eradication (633) 633
enzyme inhibitors - therapeutic use (631) 631
gastroenterology and hepatology (624) 624
prevention (612) 612
nonsteroidal antiinflammatory drugs (608) 608
anti-inflammatory agents, non-steroidal - adverse effects (606) 606
child (590) 590
efficacy (590) 590
drugs (584) 584
gerd (576) 576
peptic ulcer - drug therapy (576) 576
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18797) 18797
German (458) 458
Japanese (308) 308
Spanish (306) 306
French (295) 295
Korean (256) 256
Russian (191) 191
Chinese (69) 69
Italian (51) 51
Czech (46) 46
Polish (45) 45
Hungarian (38) 38
Portuguese (32) 32
Dutch (31) 31
Norwegian (16) 16
Danish (14) 14
Swedish (14) 14
Finnish (9) 9
Ukrainian (9) 9
Romanian (7) 7
Turkish (7) 7
Croatian (6) 6
Slovak (6) 6
Icelandic (2) 2
Bulgarian (1) 1
Indonesian (1) 1
Lithuanian (1) 1
Persian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2016, Volume 14, Issue 6, pp. 809 - 815.e1
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 07/2017, Volume 27, Issue 13, pp. 2962 - 2966
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2016, Volume 78, Issue 1, pp. 41 - 49
The Hedgehog pathway inhibitor vismodegib exhibits pH-dependent solubility, and in vitro studies have shown that vismodegib is a substrate of P-glycoprotein... 
Medicine & Public Health | CYP inhibitors | Clinical pharmacology | Oncology | Cancer Research | Pharmacology/Toxicology | Clinical drug–drug interaction | Pharmacokinetic | Proton-pump inhibitor | P-glycoprotein inhibitor | SINGLE | HUMAN PLASMA | ORAL ABSORPTION | MASS-SPECTROMETRY | GDC-0449 | ONCOLOGY | Clinical drug-drug interaction | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | HEDGEHOG SIGNALING PATHWAY | SOLID-PHASE EXTRACTION | Fluconazole - pharmacology | Proton Pump Inhibitors - pharmacology | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Area Under Curve | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Fluconazole - administration & dosage | Solubility | Pyridines - pharmacokinetics | Anilides - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Itraconazole - pharmacology | Cytochrome P-450 CYP2C9 Inhibitors - administration & dosage | Cytochrome P-450 CYP2C9 Inhibitors - pharmacology | Drug Interactions | Anilides - administration & dosage | Proton Pump Inhibitors - administration & dosage | Rabeprazole - pharmacology | Female | Itraconazole - administration & dosage | Hydrogen-Ion Concentration | Rabeprazole - administration & dosage | Drug interactions | Cytochrome P-450 | Index Medicus | Original
Journal Article
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 10/2017, Volume 26, Issue 10, pp. 1141 - 1148
PurposeTo assess the risk of gastrointestinal perforation, ulcers, or bleeding (PUB) associated with the use of conventional nonsteroidal anti-inflammatory... 
proton pump inhibitors | bleeding | gastrointestinal toxicity | perforation | selective COX‐2 inhibitors | ulcers | conventional NSAIDs | selective COX-2 inhibitors | RHEUMATOID-ARTHRITIS | CARDIOVASCULAR EVENTS | NONSELECTIVE NSAIDS | CELECOXIB | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CONTROLLED TRIALS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HIGH-RISK | CYCLOOXYGENASE-2 INHIBITORS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OSTEOARTHRITIS | Age Factors | Humans | Middle Aged | Peptic Ulcer - prevention & control | Male | Peptic Ulcer - epidemiology | Gastrointestinal Hemorrhage - epidemiology | Case-Control Studies | Cyclooxygenase 2 Inhibitors - adverse effects | Peptic Ulcer Perforation - epidemiology | Pain - drug therapy | Pain Management - adverse effects | Aged, 80 and over | Female | Odds Ratio | Peptic Ulcer - complications | Risk Factors | Pain Management - methods | Proton Pump Inhibitors - therapeutic use | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Peptic Ulcer Perforation - prevention & control | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Aged | Peptic Ulcer - chemically induced | Peptic Ulcer Perforation - etiology | COX-2 inhibitors | Proton pump inhibitors | Nonsteroidal anti-inflammatory drugs | Drugs | Antiinflammatory agents | Control methods | Adjustment | Toxicity | Perforation | Pharmacology | Inflammation | Regression analysis | Patients | Risk factors | Bleeding | Nonsteroidal antiinflammatory drugs | Confidence intervals | Inhibitors | Ulcers | Cyclooxygenase-2 | Health risk assessment | Index Medicus | Original Report | Original Reports
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 8, pp. 845 - 853
BACKGROUND—Proton pump inhibitors (PPIs) are gastric acid–suppressing agents widely prescribed for the treatment of gastroesophageal reflux disease. Recently,... 
dimethylarginine dimethylaminohydrolase | endothelium | proton pump inhibitors | nitric oxide | N,N dimethylarginine | N dimethylarginine | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | ENDOTHELIAL DYSFUNCTION | MYOCARDIAL-INFARCTION | NITRIC-OXIDE SYNTHASE | ACID SUPPRESSION | ADMA | DIMETHYLAMINOHYDROLASE DDAH | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | STAGE RENAL-DISEASE | ARTERY-DISEASE | Proton Pump Inhibitors - pharmacology | Humans | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Endothelium, Vascular - drug effects | Male | Arginine - analogs & derivatives | Esomeprazole - therapeutic use | Cardiovascular Diseases - epidemiology | Nitric Oxide Synthase Type III - metabolism | Gastroesophageal Reflux - drug therapy | Disease Models, Animal | Amidohydrolases - metabolism | Proton Pump Inhibitors - adverse effects | Cardiovascular Diseases - metabolism | Mice, Inbred C57BL | Risk Factors | Cells, Cultured | Biomarkers - blood | Proton Pump Inhibitors - therapeutic use | Animals | Lansoprazole - adverse effects | Endothelium, Vascular - metabolism | Arginine - blood | Lansoprazole - pharmacology | Endothelium, Vascular - pathology | Mice | Vasodilation - drug effects | Lansoprazole - therapeutic use | Gastroesophageal reflux | Complications and side effects | Usage | Care and treatment | Patient outcomes | Proton pump inhibitors | Cardiovascular diseases | Drug therapy | Health aspects | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2014, Volume 135, Issue 1, pp. 187 - 197.e4
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article